A Phase 2 interventional study of NBI-921352 in Focal Onset Seizure and Focal Onset Epilepsy, sponsored by Neurocrine Biosciences. Terminated at 26 sites in 7 countries. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
This Phase 2, prospective, interventional, active extension study was designed to evaluate the long-term safety and tolerability of NBI-921352 as adjunctive therapy in adult participants with focal onset seizures who completed 11 weeks of treatment in randomized, double-blind, placebo-controlled Study NBI-921352-FOS2021. Eligible participants may enroll directly following the completion of the Week 11 study visit of Study NBI-921352-FOS2021 or after a gap following completion of that study.
896 studies on the registry are indexed under Seizures; 145 are open to participants now.
This study's enrollment of 82 is above the median of 62 across 621 interventional studies indexed under Seizures.
Browse Seizures studies →Neurocrine Biosciences is the lead sponsor of 86 studies on the registry; 16 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Treatment for up to 107 weeks.
Drug: NBI-921352
Tablets for oral administration
The occurrence of serious treatment-emergent adverse events (TEAEs)
Time frame: Through Week 111
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zandatrigine